而与BMS的合作则要追溯至2018年的情人节,彼时BMS以36亿美元的高额代价获得了NKTR-214的部分权益。 2016年10月,一项开放标签、剂量递增和队列扩展的I/II期研究(NCT02983045)在美国、加拿大和欧洲启动,以评估nivolumab联合NKTR-214治疗局部晚期或转移性...
Ⅰ期剂量递增研究共纳入38例晚期肿瘤患者,分别是11例晚期恶性黑色素瘤,22例肾癌和5例非小细胞肺癌患者,患者接受NKTR-214联合O药的治疗,剂量分别为O药240mg(2周1次),或者360mg(3周1次),NKTR-214为0.003或者0.006 mg/kg(2周1次或3周1次),研...
EP: 2.The Hype and the Hope of Immuno-Oncology Agents EP: 3.Synergistic Activity of NKTR-214 With Nivolumab EP: 4.The PIVOT-02 Trial: NKTR-214 With Nivolumab EP: 5.Pathophysiology of the Tumor Microenvironment in Melanoma EP: 6.Pegylation Chemistry of NKTR-214 in Melanoma EP: 7.PIVOT...
患者接受NKTR-214(0.003mg/kg或0.006mg/kg,每二周一次或每三周一次)联合Opdivo(Nivolumab 240mg每二周一次或360mg每三周一次)。二期临床剂量确定为NKTR-214(0.006mg/kg每三周一次)联合Opdivo(360mg每三周一次)。 11例黑色素瘤的客观有效率64%,其中1名肿瘤完全缓解,另1名的肿瘤完全缓解未确认,疾病控制率91%,...
Combining the CD122-biased cytokine NKTR-214 with the PD-1 inhibitor nivolumab (Opdivo) showed promising antitumor activity, particularly in PD-L1–negative patients.
2.《NKTR-214 (CD-122-biased agonist) plus nivolumabin patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT》 参考来源: 1.nektar.com/application/ 2.nektar.com/application/ 作者:春风健康海外就医购药服务机构总编 - 采菽 ...
生物谷百时美施贵宝(BMS)合作伙伴Nektar Therapeutics近日在2019年癌症免疫治疗学会(SITC)年会上公布了I/II期PIVOT-02研究中bempegaldesleukin(BEMPEG,NKTR-214)与Opdivo(欧狄沃,通用名:nivolumab,纳武…
在2019年癌症免疫疗法学会(SITC)年会上,Vaccibody介绍了一组患有各种实体瘤的患者中VB10.NEO的中期数据,这些患者均接受了多线先前的抗癌治疗并接受过至少一种检查点抑制剂(CPI)(nivolumab或pembrolizumab)治疗5到32个月。呈现的数据显示,接受VB10.NEO治疗的患者中有50%(7/14)达到了临床反应,包括4位SCCHN患者。临...
IL-2 pathway, provides sustained signaling through the heterodimeric IL-2 receptor pathway (IL-2R尾纬) to preferentially activate and expand NK and effector CD8+ T cells over T-regulatory cells, and is currently in multiple phase I, II and III clinical trials in combination with nivolumab. He...
All dose cohorts of NKTR-214 and nivolumab demonstrate a favorable safety profile and are well-tolerated. In the study to-date, there are no dose-limiting toxicities, no grade 3 or higher treatment-related AEs, and no immune-related AEs (such as colitis, dermatitis, pneumoniti...